UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer

UNICANCER-PACS08 compared adjuvant FEC (5-FU; epirubicin; cyclophosphamide) then docetaxel to FEC then ixabepilone in poor prognosis early breast cancer (BC). We evaluated whether replacing docetaxel with ixabepilone would increase 5-year disease-free survival (DFS).

Source: European Journal of Cancer - September 26, 2018 Category: Cancer & Oncology Authors: Mario Campone, Magali Lacroix-Triki, Lise Roca, Marc Spielmann, Hans Wildiers, Paul Cottu, Pierre Kerbrat, Christelle Levy, Isabelle Desmoulins, Thomas Bachelot, Tan Winston, Jean-Christophe Eymard, Lionel Uwer, Francois P. Duhoux, Didier Verhoeven, Domin Tags: Clinical Trial Source Type: research